KBI Biopharma Selects Freeslate’s Biologics Formulation System for Early and Late Stage Drug Development
04 Sep 2013

Freeslate, Inc., the leading provider of high throughput research solutions, today announced that KBI Biopharma, Inc. (KBI), a leading development and contract manufacturing organization serving the biopharmaceutical industry, has purchased Freeslate’s Biologics Formulation System to help develop more robust formulations using less time and material. The Biologics Formulation System is based on Freeslate’s Core Module 3 (CM3) automation platform and provides a new, high throughput research approach to address challenges in biologics formulation.

“The KBI team is excited to begin using Freeslate’s Biologics Formulation System to support our biologics formulation screening during early-stage development, as well as formulation robustness studies and process optimization during later stage development”, said Joseph McMahon, President and CEO for KBI. “We selected Freeslate’s technology because the system was designed for biologics formulation, combining key capabilities that can be used across both early and late stage development projects allowing us to screen a broader range of conditions and reduce product consumption while accelerating our clients’ development timelines.”

“At Freeslate, we are dedicated to advancing biologics formulation with integrated, automated solutions that address the complex problems of drug development,” said John S. Senaldi, President and CEO of Freeslate. “We have built strong capabilities in this area and are pleased to partner with KBI to continue those advances and support the important research they are doing on behalf of their clients.”

Freeslate’s Biologics Formulation System supports the entire formulation development process through the combination of automated sample prep and new high throughput capabilities for pH measurement, viscosity measurement, and visual inspection/particle counting. The system also integrates with critical analytics like Dynamic Light Scattering, High Pressure Liquid Chromatography, and UV/VIS plate readers. It enables users to develop more candidates, with more robust formulations, in a shorter period of time, with less material, with no increase in personnel. By both generating and managing data from orthogonal analytics, the system helps drive informed decision making.

KBI will serve as a reference site for Freeslate, hosting customers, product demonstrations, and participating in speaking engagements and seminars to help educate others on the available high throughput research tools. The two companies will also collaborate on future product development.

Request Info


Company website

Freeslate
profile photo

Sarah Thomas
Editorial Assistant